Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging, announced today that Sirtris, together with
leading sirtuin researchers David A Sinclair, Ph.D. and Leonard P.
Guarente, Ph.D., published a review in the MIT Tech Review
entitled “Developing Drugs to Treat Diseases
of Aging.”
The review highlights the discovery of sirtuins, a novel class of
enzymes, and their role in the aging process. Additionally, the article
discusses the drug development path of SIRT1 activators as potential
treatments for a range of diseases of aging including metabolic
disorders such as Type 2 Diabetes, mitochondrial disorders such as
MELAS, neurological disorders, and cancer.
“This review summarizes the growing body of
evidence regarding the substantial therapeutic potential of SIRT1
activators, such as SRT501, our proprietary formulation of resveratrol,
and new chemical entities which are 1000 times more potent than
resveratrol, to address a broad range of diseases of aging,”
said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris
Pharmaceuticals, Inc.
David A. Sinclair, Ph.D. is a scientific co-founder, member of the Board
of Directors of Sirtris Pharmaceuticals, Associate Professor of
Pathology at Harvard Medical School, and Director of the Glenn
Laboratories for the Biological Mechanisms of Aging. Leonard P. Guarente
is the Novartis Professor of Biology at the Massachusetts Institute of
Technology.
The article can be accessed at:
http://www.technologyreview.com/Biotech/19238/
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators for multiple neurodegenerative diseases and
other types of disorders, the progress and results of pre-clinical
studies of SIRT1 activators, and the potential of sirtuin modulators to
receive regulatory approval. These forward-looking statements about
future expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company's product candidates has received regulatory approvals, the
potential inability of the Company to gain market acceptance of the
Company's product candidates, and those other risks factors that can be
found in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.